Denmark
Lophora, founded in 2018 and headquartered in Denmark, is a clinical-stage CNS drug discovery company committed to developing next-generation neuroactive medicines. The company focuses on treating neurological and psychiatric disorders such as depression, anxiety, mood disorders, PTSD, and substance use disorders. Aspiring to change the landscape of mental health treatment, Lophora prides itself on their slogan, "Developing Next Generation Neuroactive Medicines to Treat Mental Illness."
The company has garnered attention for its lead candidate, LPH-5, which has successfully completed in vivo efficacy characterization and GLP-Tox studies. They're setting the stage to initiate first-in-human trials by 2024, with a planned CTA submission by Q2 2024.
Financially, Lophora recently raised kr10.00M through a Convertible Note investment on 31 March 2020, led by the BioInnovation Institute. Additional support has come from the BII (Novo Nordisk Foundation) and seasoned biotech investors, setting the foundation for future growth and clinical advancements.
